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a  b  s  t  r  a  c  t
We  report  anti-cancer  activity  of ZnO  thin-ﬁlm-coated  chips  by sustained  release  of zinc  ions.  ZnO  chips
were  fabricated  by  precisely  tuning  ZnO  thickness  using  atomic  layer  deposition,  and  their  potential  to
release  zinc  ions  relative  to  the  number  of deposition  cycles  was  evaluated.  ZnO  chips  exhibited  selec-
tive  cytotoxicity  in human  B  lymphocyte  Raji  cells  while  having  no  effect  on  human  peripheral  blood
mononuclear  cells.  Of importance,  the  half-maximal  inhibitory  concentration  of the  ZnO  chip  on  the  via-
bility  of  Raji  cells  was  121.5  cycles,  which  was  comparable  to 65.7  nM  of daunorubicin,  an  anti-cancer
drug  for  leukemia.  Molecular  analysis  of cells  treated  with  ZnO  chips  revealed  that  zinc  ions  released
from  the  chips  increased  cellular  levels  of  reactive  oxygen  species,  including  hydrogen  peroxide,  which
led to the  down-regulation  of anti-apoptotic  molecules  (such  as HIF-1,  survivin,  cIAP-2,  claspin,  p-53,ancer and  XIAP)  and  caspase-dependent  apoptosis.  Because  the  anti-cancer  activity  of  ZnO  chips  and  the  mode
of action  were  comparable  to  those  of  daunorubicin,  the  development  and  optimization  of  ZnO  chips
that  gradually  release  zinc  ions  might  have  clinical  anti-cancer  potential.  A further understanding  of the
biological  action  of ZnO-related  products  is  crucial  for  designing  safe  biomaterials  with  applications  in
disease treatment.
©  2016  The  Authors.  Published  by Elsevier  Ireland  Ltd.  This  is an  open  access  article  under  the  CC  BY. Introduction
Multifunctional zinc oxide (ZnO) has been used in various forms
uch as nanoparticles (NPs) or nanorods for biomedical applica-
ions including biosensing, imaging, drug delivery, and clinical
mplants [23,31,44,46]. Since several studies have reported the tox-
city of ZnO materials, their potential to induce cell death has been
xplored in cancer biology. The anti-cancer activity of ZnO nano-
aterials has been described, and additive or synergistic effects of
nO NPs with anti-cancer compounds (or drugs) on the induction
f apoptosis in cancer cells also have been reported [10,43].
The effects of zinc ions might explain ZnO-induced cytotoxic and
poptotic activity. Zinc ions released from ZnO materials induce
xidative stress-mediated cell death [3,6,30,40], and the strong
orrelation between ZnO NP-induced cytotoxicity and free zinc
on concentration also suggests a requirement for ZnO dissolution
or effective cytotoxicity [36]. Consistently, extracts exhibit more
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cytotoxicity in suspended cells than do nanostructured ZnO chip
coatings per se [30]. These ﬁndings motivated us to fabricate a ZnO
chip that gradually releases zinc ions and to evaluate its anti-cancer
activity. The cytotoxicity of the ZnO chip was  compared to that
of daunorubicin (an anti-cancer drug used to treat leukemia) in
human B lymphocyte Raji cells. After using inductively coupled
plasma (ICP) atomic emission spectroscopy (AES) to analyze the
zinc ion concentration released from the ZnO chip, we evaluated
the cytotoxicity of zinc ions released from the chip in Raji cells
and human peripheral blood mononuclear cells (PBMCs). In addi-
tion, using a cellular peroxidase activity assay, antibody array, and
Western blot analysis, we investigated the mechanism underlying
the anti-cancer activity of zinc ions.
2. Materials and methods
2.1. Fabrication of the ZnO chipZnO chips were fabricated by coating ZnO onto circular glass
slides that ﬁt in a 6-well culture plate using an atomic layer depo-
sition (ALD) method. ALD is a thin ﬁlm-coating method based on
the sequential use of a gas-phase chemical reaction. A single cycle
article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Fig. 1. Growth of ZnO thin ﬁlms and its characteristics. (A) A schematic depiction of ALD-processed ZnO thin ﬁlm with different thickness. (B) A 6-well plate-sized glass















6 plot of surface roughness (D), analyzed by AFM, versus the number of ALD cycles, 
f ALD consists of a pulse of diethyl zinc (DEZ) followed by a
urge process. This step is then followed by a subsequent pulse of
ater (oxidant) to form a layer of ZnO. The ALD method enables
tomic-scale control of the thickness of ZnO thin ﬁlms, with a
hip undergoing 200 cycles of this process characterized as a 200-
ycle ZnO chip. ALD was performed in a Lucida D-100 chamber
sing DEZ (Sigma-Aldrich, MO,  USA) with water as the reactant
nd oxidant, respectively. ALD was carried out under full satura-
ion conditions, with DEZ–purge–water–purge cycles controlled
t 0.5 s–10 s–0.1 s–30 s. The deposition temperature was ﬁxed at
50 ◦C.
.2. ICP-AES analysisAfter the ZnO chip was incubated with cell culture media, the
oncentration of zinc ions in the media was analyzed using an iCAP
500 (Thermo Scientiﬁc, MA,  USA).tively.
2.3. Cell culture
A549 cells and Raji cells were purchased from ATCC (VA,
USA) and cultured with DMEM and RPMI-1640 containing 10%
heat-inactivated fetal bovine serum and 1% antibiotics (100 U/ml
penicillin and 100 g/ml streptomycin) in a humidiﬁed atmosphere
of 5% CO2 at 37 ◦C, respectively. All cell culture materials were pur-
chased from Hyclone (UT, USA). Human PBMCs and culture medium
were purchased from Zen-Bio Inc. (NC, USA).
2.4. Apoptosis analysis
Cells (2 × 105 cells/ml) were incubated in the culture plate with
the ZnO chip or with daunorubicin (Selleckchem, TX, USA) or the
extracts containing zinc ions, for the indicated time. Then, using
MuseTM Annexin V and the Dead Cell Assay kit (Millipore, MA,  USA),
live and apoptotic populations were measured in a MuseTM Cell
Analyzer (Millipore).
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Fig. 2. ZnO chips release zinc ions and induce apoptosis of Raji cells in a ZnO deposition cycle-dependent manner. (A) Concentration of zinc ions in media incubating chips for
24  h was  measured by ICP analysis (presented as ‘new’). The used chips were re-incubated with the fresh media for an additional 24 h, and the concentration of zinc ions in
media  was  measured (presented as ‘used’). (B) Monolayer A549 cells were seeded onto ZnO chips. After 24 h of incubation, non-adherent cells were discarded, and attached
cells  were counted under a light microscope. **, P < 0.01; ***, P < 0.001 versus chips without ZnO. (C) The apoptotic activity of ZnO chips in Raji cells was evaluated. Raji cells
were  incubated on built-in various cycles of ZnO chips for 24 h, and then the number of apoptotic cells was measured in a MuseTM Cell Analyzer by using MuseTM Annexin V
and  the Dead Cell Assay kit. The IC50 value was  determined from the ZnO deposition cycle-dependent apoptotic cell number curve using GraphPad Prism software (GraphPad
Software, Inc., CA, USA). (D) The apoptotic activity of daunorubicin was  also evaluated in Raji cells. The IC50 value was  determined from the concentration-dependent apoptotic












Zsing  the MuseTM MultiCaspase kit. The percent of caspase-positive cells is given. (
nO  chips or 100 M daunorubicin. Nuclear fragmentation was observed by PI stain
.5. Caspase assay
Caspase activity was measured using the MuseTM MultiCaspase
it (Millipore) according to the manufacturer’s protocol. This pan-
aspase assay can detect the presence of multiple caspases (i.e.,
aspase-1, 3, 4, 5, 6, 7, 8, and 9). Brieﬂy, Raji cells (2 × 105 cells/ml)
ere incubated in the culture plate with the ZnO chip or with
aunorubicin for 24 h and harvested. Then, live caspase-positive
nd necrotic populations were measured in the MuseTM Cell Ana-
yzer..6. Propidium iodide (PI) staining
Raji cells (2 × 105 cells/ml) were incubated with a 400-cycle
nO chip or with daunorubicin (100 M)  for 24 h. Then, cells wereresentative images of nuclear changes in Raji cells after incubating with 400-cycle
stained with 1 g/ml PI (Clontech, CA, USA) in the dark at room
temperature for 15 min, and images of cells were captured at a
magniﬁcation of ×40 in an ImageStream ﬂow cytometer (Amnis,
WA,  USA).
2.7. Conductivity and surface roughness measurement
Hall measurements were conducted using the HMS-3000
(Ecopia, South Korea) in the Van der Pauw conﬁguration. To ensure
proper electrical measurement, the induced current was  ﬁxed to
1 mA.  A thermal annealing treatment was  conducted on a hot plate.
A Dimension 3100 atomic force microscope (AFM; Veeco, NY, USA)
was employed to obtain topological images and conﬁrm surface
roughness.
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Fig. 3. Apoptotic activity of ZnO chips is due to the released zinc ions, not electrical conductivity. (A) A scheme of Hall’s measurement. (B) The electrical conductivity of
ZnO  chips with respect to the number of ALD cycles. (C) The conductivity of 400-cycle ZnO chips was  measured after 250 ◦C thermal annealing treatment (black dots). The
amount of released zinc ions in 400-cycle ZnO chips after thermal annealing treatment was measured by ICP analysis after incubation with culture media for 24 h (orange
















(ars).  (D) The effect of thermal annealing time on the number of apoptotic Raji cells
he  percent of apoptotic cell number is presented.
.8. Cellular peroxidase activity assay
Cellular peroxidase activity was measured using the Amplex
ed Hydrogen Peroxidase assay kit (Invitrogen, CA, USA) according
o the manufacturer’s protocol. Brieﬂy, Raji cells (2 × 105 cells/ml)
ere incubated with or without a 400-cycle ZnO chip for the indi-
ated time, and the cellular peroxidase activity then was  measured
t Ex530 nm and Em590 nm in a Wallac EnVision microplate reader
PerkinElmer, MA,  USA).
.9. Oxidative stress measurement
Oxidative stress was measured using the MuseTM Oxidative
tress kit (Millipore) according to the manufacturer’s protocol.
rieﬂy, Raji cells (2 × 105 cells/ml) were incubated in the culture
late with a ZnO chip or with daunorubicin for the indicated time.
hen, live cells and cells with signs of ROS were distinguished and
ounted in the MuseTM Cell Analyzer..10. Western blotting analysis
In the absence or presence of zinc ions (10 mg/l), Raji cells
5 × 105 cells/ml) were incubated for 3 or 12 h, washed withvaluated using the MuseTM Cell Analyzer. Cells were incubated with chips for 24 h.
ice-cold phosphate-buffered saline, and lysed in lysis RIPA buffer
(Elpis Biotech, Daejeon, Korea) containing 1× protease and phos-
phatase inhibitors (Pierce Biotechnology, IL, USA). Cell lysates were
subsequently incubated at 4 ◦C for 20 min  and then centrifuged at
14,000g for 15 min. The protein concentration of the supernatants
was determined using a protein assay kit (Bio-Rad, CA, USA), and
denatured proteins (20 g) were loaded in a 10% SDS–PAGE gel,
followed by transfer by electroblotting to a PVDF membrane (Mil-
lipore, CA, USA). Membranes were incubated with the blocking
buffer consisting of TBST buffer (10 mM Tris–HCl pH 7.5, 150 mM
NaCl, 0.1% Tween 20) and 5% nonfat dry milk for 2 h, and then
incubated with the primary antibodies diluted with the blocking
buffer (1:1000) overnight at 4 ◦C. The membranes were washed
with TBST at room temperature and incubated with diluted sec-
ondary antibodies (1:5000) for 1 h. After being washed with TBST
three times (15 min  each), the membranes were developed with the
SuperSignal West Femto Maximum Sensitivity Substrate (Pierce
Biotechnology) using a LAS-3000 luminescent image analyzer (Fuji
Photo Film Co., Ltd., Japan). The antibody against actin and sec-
ondary antibodies were purchased from Santa Cruz Biotechnology
(CA, USA). All other antibodies were purchased from Cell Signaling
Technology (MA, USA).
434 S.-H. Moon et al. / Toxicology Reports 3 (2016) 430–438
Fig. 4. ZnO chips selectively induce apoptosis of Raji cells with induction of ROS. Apoptotic activity of zinc ions released from chips was evaluated in Raji cells (A) and PBMCs
( lex Re



















AB)  using the MuseTM Cell Analyzer. (C) ROS generation was  evaluated with the Amp
r  a 400-cycle ZnO chip. *, P < 0.05; **, P < 0.01; ***, P < 0.001. (D) Oxidative stress wa
he  red M2  gate (Supplementary Fig. 2) is presented.
.11. Human apoptosis array analysis
Human apoptosis array analysis was carried out according to
he manufacturer’s protocol. Brieﬂy, in the absence or presence of
inc ions (10 mg/l), Raji cells (5 × 105 cells/ml) were incubated for
 or 12 h and solubilized by lysis buffer. After protein quantiﬁca-
ion, cell lysates (400 g) were adjusted to 1.5 ml  with lysis buffer
nd probed to the pre-coated Human Apoptosis Array membrane
Human Apoptosis Array, R&D Systems, MN,  USA) at 4 ◦C overnight.
hen, array dots in the membrane were developed and quanti-
ed with the LAS-3000 luminescent image analyzer (Fuji Photo
ilm Co., Ltd., Japan). Densitometric analysis was performed using
mageJ software and the relative, normalized expression level of
ach molecule to the reference spots presented.
.12. Statistical analysis
All quantitative values are presented as mean ± SD. Statistical
ifferences were analyzed using Student’s t test. A value of P < 0.05
as considered signiﬁcant.
. Results and discussion.1. Fabrication and characterization of ZnO chip
ZnO thin ﬁlms were deposited on glass substrates using the
LD method (Fig. 1A). As shown in Fig. 1B, ZnO chips are opticallyd Hydrogen Peroxidase assay kit after Raji cells were cultured with glass substrate
sured using the MuseTM Oxidative Stress kit. The percent of cells exhibiting ROS  in
transparent. To investigate the surface characteristics of ZnO chips,
we used AFM in non-contact mode. AFM images of ZnO chips
deposited in different numbers of ALD cycles are shown in Fig. 1C,
and the analysis of the surface roughness is shown in Fig. 1D.
3.2. Potential of ZnO chip to release zinc ions and induce
apoptosis in Raji cells
The amount of zinc ions released from the ZnO chip in the cul-
ture media was evaluated by ICP-AES (Fig. 2A). When ZnO chips
were incubated in culture media (5 ml)  in a 6-well culture plate for
24 h, the amount of released zinc ions gradually increased accord-
ing to the ZnO deposition cycle number, but after 200 cycles, it was
likely to be saturated to 10 mg/l. When the used ZnO chips (that
were incubated with the culture media for 48 h) were re-incubated
for 24 h after being washed in phosphate-buffered saline, zinc ions
were still released from ﬁlms, and consistent with new chips, satu-
ration was likely to 10 mg/l. These results suggested that ZnO thin
ﬁlms on the chip could continuously and slowly release zinc ions
and that the amount released might be isotonically saturated.
Next, we investigated whether the ZnO chip could affect the
viability of cancer cells. First, a monolayer of human lung epithe-
lial adenocarcinoma A549 cells was  applied to ZnO chips. When
A549 cells were seeded onto ZnO chips in a 6-well culture plate, the
number of attached A549 cells was signiﬁcantly decreased accord-
ing to the number of ZnO deposition cycles (Fig. 2B). Considering
that there was  no difference in the surface roughness between
150–400 deposition cycles (Fig. 1D), this result suggested that the
































cig. 5. Zinc ions down-regulate anti-apoptotic proteins. The effects of zinc ions
n  the expression of apoptosis-related proteins were conﬁrmed by Western blot
nalysis. Actin was used as a loading control.
hysicochemical properties of ZnO chips might affect the attach-
ent of A549 cells, including the sustained release of zinc ions.
Because cell type-dependency or other complicated physico-
hemical properties of ZnO in aqueous conditions could affect the
ttachment of A549 cells, the suspended Raji cells were chosen and
pplied for evaluation of the anti-cancer activity of ZnO chips. Raji
ells were incubated in the culture plate with ZnO chips or with
aunorubicin for 24 h, then stained with Annexin V and the Dead
ell kit, and acquired on the cell analyzer. As shown in the plots
Supplementary Fig. 1A and B), viable cells (lower left), cells in
he early stages of apoptosis (lower right), cells in the late stages
f apoptosis or dead by apoptotic mechanisms (upper right), and
ells that had died via necrosis but not through the apoptotic path-
ay (upper left) were displayed as dots. Glass slides did not affect
he viability of suspended Raji cells, but ZnO deposition increased
he number of apoptotic cells in a ZnO deposition cycle-dependent
anner. Although ZnO-mediated toxicity to cancer cells has been
uggested to result from direct contact between materials and cells
26], the apoptosis of the suspended Raji cells in the ZnO chip
ight be explained by the effect of zinc ions released from the
hip. The half-maximal inhibitory concentration (IC50) of the ZnO
hip on the viability of Raji cells was 121.5 cycles (Fig. 2C), and
hat of daunorubicin was  65.7 nM (Fig. 2D). Thus, a 121.5-cycle ZnO
hip could clinically exhibit anti-cancer activity similar to that of
5.7 nM daunorubicin. Furthermore, the number of apoptotic Raji
ells was dramatically increased to 98% in the culture condition
ith a 200-cycle ZnO chip or 1 M daunorubicin.
In addition, as shown in Supplementary Fig. 1C, the MultiCas-
ase assay revealed that the apoptotic activity of the ZnO chip
as strongly dependent on the induction of caspases; when Raji
ells were cultured with a 400-cycle ZnO chip, 60% of cells wereports 3 (2016) 430–438 435
caspase-positive (Fig. 2E). Also, Raji cells incubated with the ZnO
chip and daunorubicin displayed nuclear fragmentation, a hallmark
of apoptosis (Fig. 2F).
3.3. Apoptotic activity of the ZnO chip because of released zinc
ions, not electrical conductivity
Having shown that zinc ions were sustainably released in a
ZnO deposition cycle-dependent manner and demonstrated apo-
ptosis of Raji cells, we thought that it was highly likely that the
released zinc ions were responsible for the observed Raji cell apo-
ptosis. However, another possibility was electrical conductivity of
the ZnO chips. In ALD-grown ZnO thin ﬁlms, electrical conductivity
of the ﬁlm increases in a ZnO deposition cycle-dependent manner
as well. Although the electrical conductivity of ZnO chips is unlikely
to have affected the viability of suspended Raji cells, we  never-
theless addressed the possibility. As shown in Fig. 3A, when the
electrical conductivity of ZnO chips was measured, it was increased
in a ZnO-deposited cycle-dependent manner (Fig. 3B). Electrical
conductivity of ZnO can be tuned by post-annealing [29], and it is
possible to fabricate ZnO thin ﬁlms with the same thickness but
dramatically different electrical conductivities. When 400-cycle
ZnO thin ﬁlm was annealed at 250 ◦C, its conductivity was  grad-
ually decreased by increasing thermal annealing time (black dots
in Fig. 3C). However, the change in thermal annealing time in a
400-cycle ZnO chip did not change the amount of released zinc
ions (orange bars in Fig. 3C) or the number of apoptotic Raji cells
(Fig. 3D). In the 400-cycle ZnO chip, 13 mg/l of zinc ions was
released and induced apoptosis in 98% of Raji cells. These results
conﬁrm that the apoptotic activity of the ZnO chip did not originate
from electrical conductivity.
3.4. Selective apoptotic activity of ZnO chips
Another question in the context of the anti-cancer activity of the
ZnO chip is whether it affects the viability of normal cells. Therefore,
the effect of the ZnO chip on the viability of Raji cells was  compared
to that of normal PBMCs. Because of the dramatic induction of apo-
ptosis in Raji cells with the 200-cycle ZnO chip and the release of
10 mg/l zinc ions (Fig. 2A), we  incubated Raji cells and PBMCs with
culture media containing 10 mg/l zinc ions for 1–24 h and analyzed
cell apoptosis. As shown in Fig. 4A and B, 10 mg/l zinc ions time-
dependently increased the number of apoptotic Raji cells, but not
PBMCs, suggesting that the ZnO chip could selectively induce apo-
ptosis in cancer cells rather than in normal cells. Indeed, ZnO NPs
consistently have been reported to selectively (or preferentially)
induce apoptosis in cancer cells rather than normal cells [3,19].
The selectivity of ZnO-related biomaterials should be considered
before they are applied for a clinical purpose.
3.5. ROS-inducing activity of ZnO chips in Raji cells
A remaining question was how zinc ions trigger apoptosis in Raji
cells. To elucidate the mechanism underlying the anti-cancer activ-
ity of the ZnO chip, we carried out the cellular peroxidase activity
assay to indirectly measure the level of hydrogen peroxide gener-
ated by zinc ions. Oxidative stress resulting from reactive oxygen
species (ROS) induces cancer cell apoptosis [22,28] and ZnO NPs
increase the production of hydrogen peroxide, a ROS, to induce
cell death [9,17]. Here, we found that cellular peroxidase activity
was signiﬁcantly induced when Raji cells were incubated with a
400-cycle ZnO chip (Fig. 4C). As shown in Supplementary Fig. 2,
ROS-negative live cells in the blue M1  gate and ROS-positive cells
in the red M2  gate were counted using the Oxidative Stress assay
based on the intracellular detection of superoxide radicals. When
Raji cells were incubated with the 400-cycle ZnO chip for 24 h, 67%


















iFig. 6. A schematic model presenting the ZnO chip
f cells were ROS-positive while about 47% of cells treated with
00 nM daunorubicin for 12 h were ROS-positive (Fig. 4D). These
ndings suggested that the increase in cellular oxidative stress by
he ZnO chip could be involved in its apoptotic activity
.6. Zinc ions down-regulate anti-apoptotic molecules in Raji cells
Next, the nitrocellulose membrane array containing 35 dif-
erent capture antibodies printed in duplicate was  applied for
valuation of the effect of zinc ions on the expression levels of
poptosis-related proteins. As shown in Supplementary Fig. 3,
he antibody-based apoptosis array analysis revealed that zinc
ons down-regulated protein levels of anti-apoptotic molecules,
ncluding inhibitor of apoptosis proteins (IAPs), claspin, and phos-
horylated forms of p53 and hypoxia inducible factor (HIF)-1 in
aji cells. The down-regulation of anti-apoptotic molecules by zinc
ons were further conﬁrmed by Western blot analysis (Fig. 5).Consistent with the report showing the signiﬁcant down-
egulation of survivin by ZnO nanorods in cancer cells [2], the
rotein level of survivin in Raji cells was dramatically decreased by
ncubation with zinc ions for 3 h. This rapid reduction could be theogical potential to induce apoptosis of cancer cells.
result of proteasomal degradation because the proteasomal degra-
dation of survivin has been reported as an apoptotic mechanism in
cancer cells [11,15,37].
Zinc ions also down-regulated the protein level of cIAP-2 but
not of X chromosome-linked IAP (XIAP) in Raji cells. Selective IAP
down-regulation by pharmacological inhibition has been recently
suggested to enhance the sensitization of leukemia cells to tumor
necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced
apoptosis [47]. Because anti-cancer compounds can potentiate
TRAIL-mediated death of cancer cells accompanied by induction of
ROS and the down-regulation of anti-apoptotic molecules includ-
ing survivin, cIAPs, and XIAP [20], ROS-generating ZnO materials
might be used as a potent TRAIL sensitizer for cancer treatment
[32,45].
In addition, claspin might be used to determine the sensitivity
of cancer cells to zinc ions [21]. Cleavage and degradation of claspin
during apoptosis have been reported [34], and recently, it has been
shown to positively affect the survival of cancer cells [7].Oxidative stress and cytotoxicity induced by ZnO nanomaterials
also could be explained by the status of p53. Mutant p53 proteins


































































[S.-H. Moon et al. / Toxico
ancers [18], commonly called ‘mutant p53 gain of oncogenic
unction’. One of the potential molecular mechanisms underlying
he gain of function of mutant p53 is a role as an oncogenic tran-
cription factor [38]. Apparently, mutant p53 exhibits increased
umorigenicity in vivo and enhances resistance to anti-cancer drugs
sed clinically [1,5]. Moreover, post-translational modiﬁcation of
utant p53, such as phosphorylation, has been suggested to con-
ribute to tumorigenesis [39]. Of importance, the phosphorylation
f mutant p53 at Ser392 regulates its oncogenic function [42];
oreover, inhibition of mutant p53 phosphorylation at Ser15 or
er315 has been suggested to restore its tumor suppressor func-
ion [39]. As is typical for Burkitt lymphoma, Raji cells used in this
tudy have a p53 mutation [12]. Therefore, the zinc ion-mediated
own-regulation of p-p53 in Raji cells could lead to apoptosis via
educed oncogenic activities. Similar to our results, ZnO NPs induce
xidative stress-mediated apoptosis in cancer cells via the p53
athway [3]. In addition, p53 deﬁciency enhances susceptibility to
nO-induced cancer cell death in a ROS-dependent manner [35],
ut here, the total p53 expression level was not changed by zinc
ons.
The transcription factor HIF-1 regulates the expression of
umerous genes involved in cellular metabolism, cell cycle reg-
lation, angiogenesis, and inhibition of apoptosis. HIF-1  and its
ignaling pathway in cancer cells are related to the role of p53
nd/or ROS [16,33]. In addition, HIF-1 is activated aberrantly in
ematological malignancies [8,14], and inhibition of its activity cor-
elates with sensitization of chemo-resistant cells to apoptosis [27].
ere, incubation with zinc ions for 12 h strongly down-regulated
he protein expression level of HIF-1.  Inhibiting HIF-1  signaling
y reducing its protein level or its transcriptional activity has been
onsidered as an anti-cancer strategy to overcome drug resistance
o chemotherapy [41].
. Conclusion
In summary, we fabricated chips deposited with ZnO thin ﬁlms
nd characterized their anti-cancer activity by the release of zinc
ons in a ZnO deposition cycle-dependent manner, independent
f conductivity. The caspase-dependent apoptotic activity of ZnO
hips could be the result of the potential of zinc ions to induce
xidative stress and down-regulate protein levels of anti-apoptotic
olecules including IAPs, claspin, p-p53, and HIF-1 in Raji cells
Fig. 6). Through apoptosis analysis, the IC50 of ZnO was for the ﬁrst
ime quantitatively assessed as 121.5 cycles. Because oral adminis-
ration of ZnO NPs can cause injury to the liver, kidney, and lung in
ealthy adult mice [13], a ZnO chip with a gradual release of zinc
ons might be applied topically to inhibit skin cancers [4]. In addi-
ion, along with cream-based topical therapeutics, a patch-based
ersion of the ZnO chip including anti-cancer drugs might addi-
ively or synergistically induce apoptosis of skin cancers [24,25].
urthermore, ZnO per se might be used as a coating material for
rthopedic and dental implants to inhibit bacterial adhesion and
romote osteoblast growth [23]. An understanding of the cytotoxi-
ity of ZnO-related products is crucial for the further design of safe
iomaterials for their application in treating diseases like cancer.
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